ArticleDermatology and therapy2025

Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.

Vivian Y Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.